Dengue Vaccines Are the Only Way to Prevent the Rising Incidence of Dengue Infection Becoming a Major Problem in Emerging Countries
A series of dengue vaccines are available, however, only a few are effective. The first dose of the vaccine protects against a single dengue infection, and this protective effect can last for years. However, it is possible to develop vaccine-enhanced disease if patients are not immune to the dengue virus. The global incidence of dengue is rising. Vaccines are the only way to prevent a dengue infection from becoming a major issue for communities in the developing world.
The development of dengue vaccines is currently in its nascent stage, however, the growing incidence of dengue fever in Asia is creating a lucrative opportunity for pharmaceutical companies. For example, Takeda Pharmaceuticals, a leading Japanese pharmaceutical company, has recently begun regulatory submissions for its dengue vaccine candidate, TAK-003, in the EU and in dengue-endemic countries. With the help of these partnerships, the development of dengue vaccines is moving forward.
The Global Dengue Vaccine Market is estimated to account for US$ 1,262.0 Mn in terms of value by the end of 2027.
While the results of this study were underwhelming, the vaccine demonstrated its safety in over four thousand volunteers. There are also ongoing phase 3 studies in over thirty thousand volunteers in ten countries throughout Asia and the Americas. Further development of dengue vaccines will depend on how well they protect the population from the disease. The vaccine candidate must also be compatible with vector control measures. And, as with all vaccines, there is no guarantee of their effectiveness. However, the development of dengue vaccines has reached an important stage in its lifecycle. The availability of alternative dengue vaccines is likely to break the monopoly of Denvaxia(r) vaccine. And since the growth of the vaccine industry is likely to be concentrated in Asia-Pacific, the development of new vaccines may take years. The future of the dengue vaccine industry looks bright! And, with these developments, there are numerous new vaccines on the horizon.
Sanofi Pasteur has announced that it has performed additional studies of dengue vaccines. The new studies are aimed at better describing the benefit-risk profile of dengue vaccination in seronegative individuals. The results of these studies used the newly developed NS1-based assay, and blood samples were collected 13 months after the initial vaccination. These data are useful for children aged 9 and older, those with a history of dengue, and those who live in endemic areas.
Sequential vaccination has also shown promising results in the prevention of dengue. Sequential vaccination is likely to become increasingly popular as more countries adopt it as a preventative measure. As a result, firms in the global dengue vaccines industry will likely partner with researchers from the Singapore-MIT Alliance for Research and Technology. These researchers are actively seeking to develop a dengue vaccine that is both safer and more effective than existing products.
While the development of dengue vaccines has been ongoing since the 1940s, progress has recently accelerated. To create a vaccine, the vaccine must balance the immune response of humans with attenuation of the virus. Moreover, the vaccine must provide complete, long-lasting protection against four serotypes of dengue while preventing the enhancement of the disease following subsequent infections. There are many challenges in developing a dengue vaccine, including the lack of an animal model for testing and the lack of basic knowledge of the disease's pathogenesis.